Search Results 641-650 of 18356 for alopecia

1. A Study to Evaluate the Effectiveness and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma - Mayo Clinic

   0]) from acute non-hematologic toxicity (except ≤ Grade 2 neuropathy or alopecia), due to previous therapy, prior to screening. Hodgkin lymphoma (HL) with ...

2. A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab - Mayo Clinic

   However, alopecia or other Grade ≤ adverse events (AEs) not constituting a safety risk based on Investigator's judgement are acceptable. Diagnosis of any ...

3. Long-term Safety and Effectiveness Study for Participants with Advanced Tumors who are Currently on Treatment or in Follow-up in a Pembrolizumab Trial - Mayo Clinic

   alopecia) before trial treatment in Second Course Phase is started. If participant received major surgery or radiation therapy of >30 Gray (Gy), they must ...

4. A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) - Mayo Clinic

   Toxicity from prior therapies recovered to Grade ≤ 1 or subject's baseline, except for alopecia. In addition, endocrinopathies associated with prior ...

5. A Dose Escalation Study of Amivantamab in Participants with Advanced Non-Small Cell Lung Cancer - Mayo Clinic

   Toxicities from previous anti-cancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia [any grade], Grade less ...

6. A Study of Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) - Mayo Clinic

   03) > Grade 1 from previous anti-cancer therapy (including radiotherapy), except alopecia. Any grade of neuropathy from any cause. Any prior oxaliplatin ...

7. A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer - Mayo Clinic

   o Subjects with type I diabetes mellitus, hypothyroidism requiring only hormone replacement, skin disorders (such as vitiligo,psoriasis or alopecia) not ...

8. Dose-Escalation Study of cevostamab (BFCR4350A) in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) - Mayo Clinic

   Any grade alopecia;; Peripheral sensory or motor neuropathy must have resolved to Grade ≤ 2. Measurable disease defined as at least one of the following ...

9. Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations - Mayo Clinic

   therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade 2 - Albumin levels < 2.5 g/dl - Any of the following because this study ...

10. Study Of The Bria-IMT Regimen And CPI Vs Physicians' Choice In Advanced Metastatic Breast Cancer. (BRIA-ABC) - Mayo Clinic

    Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion ...